| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780610 | Gynecologic Oncology | 2018 | 9 Pages |
Abstract
ROR1 and ROR2 play distinct roles in endometrial cancer. ROR1 may promote tumor progression, similar to its role in ovarian cancer, while ROR2 may act as a tumor suppressor in endometrioid endometrial cancer, similar to its role in colorectal cancer. With several ROR-targeting therapies currently in development and phase I clinical trials for other tumor types, this study supports the potential of these receptors as therapeutic targets for women with endometrial cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
C.E. Henry, E. Llamosas, B. Daniels, A. Coopes, K. Tang, C.E. Ford,